WOODBURY, Minnesota – (BUSINESS WIRE) – October 28, 2021–
The American Society of Regional Anesthesia has selected the INSB200 â¢ poster from InSitu Biologics as its The best of the meeting presentation in Emerging Technologies for their 20 th Annual Pain Meeting in November 2021. The âBest of Meetingâ award is presented for a number of scientific presentations that are expected to have a significant impact on clinical care in the future.
INSB200 â¢, currently in preclinical development by InSitu Biologics, is a hydrogel-lipid-microparticle matrix containing ropivacaine and characterized by a two-phase release of the drug. Drugs placed in the matrix have a significantly prolonged duration of action compared to traditional and long-acting local anesthetics. The matrix, which has a unique ultrasound signal, is designed to allow a physician to visualize the placement of the drug next to a tissue target.
The emerging technologies presentation includes the results of InSitu’s first ultrasound study, which showed improved ultrasound characteristics when using INSB200 â¢, allowing precise placement of the drug in tissue. Additionally, the presentation will provide a review of preclinical data demonstrating the potential to effectively relieve pain after a single injection for more than 120 hours.
âAt a time when the healthcare community demands alternatives to opioid therapy that can provide prolonged pain relief, our investigational drug INSB200 â¢ represents a promising opportunity that we look forward to moving to clinical trials,â said Kevin Bassett, President and CEO. of biological products InSitu.
Mark Ereth, MD, medical director of InSitu Biologics and professor emeritus at Mayo Clinic College of Medicine, said, âSignificant increases in day surgery and home health care are in our future. In these settings, patients actually deserve and will demand effective pain relief without the side effects of narcotics for the first week after surgery. InSitu Biologics is committed to developing drugs like INSB200 â¢ to meet the needs of patients. “
âThe use of a drug delivery platform such as the technology developed by InSitu Biologics has the potential to prolong the effective duration of action of local anesthetics today and possibly other drugs in the future. Said Jeffrey Gadsden, medical advisory board member, MD, chief of orthopedics. , Plastics and Regional Anesthesiology, Duke University School of Medicine.
The full poster is available here.
Biological products in situ: InSitu Biologics in an emerging biotechnology company focused on the development of a multi-phase sustained-release drug delivery platform for the localized treatment of pain, cancer and infections. The Company uses disruptive technology to address unmet needs in the pain management and drug delivery markets.
INSB200 â¢ is currently in the preclinical experimental stage. It is not yet for sale in any geography.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20211028005342/en/
CONTACT: InSitu Biologics
Mark Ereth, MD
KEYWORD: MINNESOTA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SURGERY MANAGED CARE MEDICAL DEVICES GENERAL HEALTH SCIENCES MEDICAL SUPPLIES CLINICAL TRIALS FDA CARDIOLOGY BIOTECHNOLOGY ALTERNATIVE MEDICINE AIDS HEALTH RESEARCH OTHER PHARMACEUTICAL HEALTH MANAGEMENT
SOURCE: InSitu organic products
Copyright Business Wire 2021.
PUB: 10/28/2021 11:30 a.m. / DISC: 10/28/2021 11:32 a.m.
Copyright Business Wire 2021.